DGIdb - RISEDRONIC ACID Drug Record

RISEDRONIC ACID chembl:CHEMBL923 Approved

Alternate Names:

ACTONEL
M05BA07
NE-58095
RISEDRONIC ACID
RISEDRONATE
ACTONEL®
ACIDUM RISEDRONICUM
RIDRON
RISEDRONATE SODIUM
ACIDE RISÉDRONIQE
ATELVIA®
ACIDO RISEDRONICO
RISEDRONSÄURE
rxcui:73056
chembl:CHEMBL923
pubchem.compound:5245
chemidplus:105462-24-6
drugbank:00884

Drug Info:

FDA Approval	1998
Drug Indications	Bisphosphonates
FDA Approval	approved
Drug Class	small molecule
Drug Indications	antiosteoporotic agent
Year of Approval	1998
Drug Class	bisphosphonates

(3 More Sources)

Publications:

Coxon et al., 2005, Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo., Bone
Dunford et al., 2001, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates., J. Pharmacol. Exp. Ther.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Ortiz-Gómez et al., 2006, Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate., Eukaryotic Cell
Russell et al., 2007, Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy., Ann. N. Y. Acad. Sci.
Bergstrom et al., 2000, Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase., Arch. Biochem. Biophys.
Gritzalis D et al., 2015, Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase., Bioorg Med Chem Lett
Yokoyama T et al., 2015, Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase., J Med Chem
Corral-Gudino L et al., 2006, -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone., Bone
Mossetti et al., 2005, Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment., Bone

RISEDRONIC ACID FDPS

Interaction Score: 15.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name risedronate sodium, NE-58095,Actonel, Benet, Atelvia

Novel drug target Established target

Trial Name -

PMIDs:
16006204 11160603 11752352 16835450 18056045 10620343 25630225 26314394

Sources:
DTC TdgClinicalTrial TEND TTD
RISEDRONIC ACID TNFRSF11B

Interaction Score: 6.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15777635

Sources:
NCI
RISEDRONIC ACID IL1B

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16257277

Sources:
PharmGKB
RISEDRONIC ACID EHMT2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: RISEDRONATE
- Version: 01-August-2011
Alternate Names:

RISEDRONATE Primary Drug Name

Drug Info:

Drug Class bisphosphonates

Year of Approval 1998

Publications:
TdgClinicalTrial: RISEDRONATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiosteoporotic agent

Drug Class small molecule

FDA Approval approved

Publications:
NCI: RISEDRONATE
- Version: 14-September-2017
Alternate Names:

C1528 NCI drug code

Drug Info:

Publications:

Mossetti et al., 2005, Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment., Bone

DTC: RISEDRONIC ACID

Version: 02-September-2020

Alternate Names:

CHEMBL923 ChEMBL Drug ID

Drug Info:

Publications:

Gritzalis D et al., 2015, Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase., Bioorg Med Chem Lett

Yokoyama T et al., 2015, Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase., J Med Chem

PharmGKB: risedronate
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Corral-Gudino L et al., 2006, -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone., Bone
TTD: Risedronate
- Version: 2020.06.01
Alternate Names:

D0PA5S TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL923
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	risedronate sodium, NE-58095,Actonel, Benet, Atelvia
Novel drug target	Established target
Trial Name	-

RISEDRONIC ACID Drug Record

RISEDRONIC ACID chembl:CHEMBL923 Approved

Alternate Names:

Drug Info:

Publications:

RISEDRONIC ACID FDPS

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name risedronate sodium, NE-58095,Actonel, Benet, Atelvia Novel drug target Established target Trial Name -

PMIDs: 16006204 11160603 11752352 16835450 18056045 10620343 25630225 26314394

Sources: DTC TdgClinicalTrial TEND TTD

RISEDRONIC ACID TNFRSF11B

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15777635

Sources: NCI

RISEDRONIC ACID IL1B

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16257277

Sources: PharmGKB

RISEDRONIC ACID EHMT2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: RISEDRONATE

Alternate Names: RISEDRONATE Primary Drug Name

Drug Info: Drug Class bisphosphonates Year of Approval 1998

Publications:

TdgClinicalTrial: RISEDRONATE

Alternate Names:

Drug Info: Drug Indications antiosteoporotic agent Drug Class small molecule FDA Approval approved

Publications:

NCI: RISEDRONATE

Alternate Names: C1528 NCI drug code

Drug Info:

Publications: Mossetti et al., 2005, Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment., Bone

DTC: RISEDRONIC ACID

Alternate Names: CHEMBL923 ChEMBL Drug ID

Drug Info:

PharmGKB: risedronate

Alternate Names:

Drug Info:

Publications: Corral-Gudino L et al., 2006, -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone., Bone

TTD: Risedronate

Alternate Names: D0PA5S TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL923

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name risedronate sodium, NE-58095,Actonel, Benet, Atelvia

Novel drug target Established target

Trial Name -

PMIDs:
16006204 11160603 11752352 16835450 18056045 10620343 25630225 26314394

Sources:
DTC TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
15777635

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16257277

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

RISEDRONATE Primary Drug Name

Drug Info:

Drug Class bisphosphonates

Year of Approval 1998

Drug Info:

Drug Indications antiosteoporotic agent

Drug Class small molecule

FDA Approval approved

Alternate Names:

C1528 NCI drug code

Publications:

Mossetti et al., 2005, Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment., Bone

Alternate Names:

CHEMBL923 ChEMBL Drug ID

Publications:

Corral-Gudino L et al., 2006, -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone., Bone

Alternate Names:

D0PA5S TTD Drug ID